Description

Legend Biotech is seeking a Director, Consolidations & External Reporting as part of the Finance team based in Bridgewater, NJ.

Role Overview

The Director of Consolidations & External Reporting is responsible for leading the global financial consolidation process and overseeing the preparation of accurate and timely external financial reporting. This role is a key leader within Controllership, ensuring compliance with U.S. GAAP, internal policies, and all relevant regulatory requirements. The Director will drive continuous improvement in our close cycle, reporting processes, systems, and internal controls, while partnering cross-functionally to support business growth and transformation. The primary objective of the position is to close our books by consolidating our multiple reporting entities and recording all necessary eliminating entries. This role will also manage and oversee the Company's external reporting and SEC filings (Annual 20F, 6Ks, and press releases). These processes include researching, analyzing, and documenting accounting transactions, which can withstand SOX 404 documentation and external audit scrutiny within an SEC regulated environment.

Key Responsibilities

• Lead and manage the global monthly, quarterly, and annual consolidation process for the enterprise.
• Oversee intercompany eliminations, foreign currency translation, non-controlling interests, and equity method accounting.
• Reviews the Company's external financial statements and related disclosures for the Company's 6K and 20-F filings with the SEC, including the preparation of clear, concise, and referenced supporting documentation to support each filing.
• Maintain and enhance the consolidation system (OneStream), driving automation and efficiency.
• Develop and maintain global consolidation policies and procedures.
• Reviews the Company's quarterly earnings release.
• Evaluates IFRS and SEC disclosure requirements to ensure Legend's financial reporting & disclosure compliance.
• Assess current collection of data and reporting to continuously focus on process improvement.
• Oversee monitoring of SEC and IFRS accounting developments in order to remain aware of upcoming/relevant requirements that will affect accounting, financial reporting, and SEC requirements.
• Serve as the primary liaison for external audits related to consolidation and financial reporting.
• Oversee quarterly SOX documentation, testing support, and remediation activities.
• Partner with FP&A, Tax, Treasury, and business unit finance teams to ensure data integrity and timely close.
• Drive continuous improvement initiatives to shorten close timelines and enhance reporting accuracy.
• Evaluate and implement system improvements, automation opportunities, and best practices.

Requirements

• Bachelor's degree in Accounting.
• CPA strongly preferred.
• 10+ years of progressive accounting experience, including consolidations and external reporting.
• Deep knowledge of U.S. GAAP; IFRS & SEC reporting experience preferred.
• Experience leading consolidations in a large, multi-entity, multi-currency environment.
• Strong leadership skills with experience managing teams.
• Proficiency with major ERP and consolidation systems (e.g., SAP, OneStream).
• Preferred Big 4 public accounting experience.
• Preferred experience in a publicly traded or private-equity-backed organization.
• Strategic thinking with strong attention to detail and accuracy.
• Ability to manage multiple priorities and deliver results in a fast-paced environment.
• Strong problem-solving and critical-thinking capabilities.
• High integrity and commitment to maintaining confidentiality.
• Ability to influence and partner across all organizational levels.

#Li-LB1

#Li-Hybrid

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma.

Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech.

EEO Statement

It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or any other protected characteristic under applicable federal, state or local laws or ordinances.

Employment is at-will and may be terminated at any time with or without cause or notice by the employee or the company.

For information related to our privacy notice, please review: Legend Biotech Privacy Notice .